We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Tenet Healthcare to Your Portfolio
Read MoreHide Full Article
Tenet Healthcare Corp. (THC - Free Report) is well-poised for development on the back of strategic inorganic growth and cost-reduction plan.
Over the past 30 days, the company’s earnings estimates for 2019 and 2020 have been revised 17.6% and 13.6% upward, respectively. This in turn, reflects analysts' optimism on the stock.
The company flaunts a commendable earnings surprise history, having outpaced the Zacks Consensus Estimate in the trailing four reported quarters, the average being 1072.6%. This trend of consecutive estimate beats signifies the company’s operational efficiency.
The company is well-placed for growth, evident from its favorable VGM Score of A. Here V stands for Value, G for Growth and M for Momentum with the score being a weighted combination of all three factors.
Recently, the company delivered fourth-quarter 2018 adjusted net earnings of 51 cents per share, outperforming the Zacks Consensus Estimate by 112.5%. The top line has also beat the Zacks Consensus Estimate by 2.9%.
The company boasts a strong inorganic growth story. Tenet Healthcare has made numerous acquisitions, partnerships and strategic alliances, aimed primarily at boosting its scale of business, operating capacity and an expanding geographical presence. It has partnered with industry biggies like Cigna, Aetna, UnitedHealth, Humana et al.
In 2018, the company purchased the remaining ownership stake in United Surgical Partners International along with controlling interests in an ophthalmology surgery center in Pennsylvania, a single-specialty spine surgery center in Georgia, two multi-specialty surgery centers in Florida and one in Texas plus a specialty gastroenterology center in Florida. It also bought certain non-controlling ownership portions in a multi-specialty surgery center in California as well as in two surgical hospitals at Oklahoma.
Tenet Healthcare has also been divesting its businesses to focus on its core operations. The company is focused on selling its non-core and unprofitable business units to repay debt and maintain financial liquidity. Multiple divestitures made in the past three years have streamlined its operations and generated funds to clear debts.
The company sold nine Aspen facilities in the United Kingdom, eight hospitals in the United States last year and also completed the sale of three hospitals in the Chicago area earlier this January. The company has also been exploring its strategic alternatives for Conifer, which includes either a sale or a merger, a tax-efficient spin-off or a combination of alternative transactions.
The company also undertook cost-containment initiatives that helped it lower its targeted expenses in 2018. The cost-management program comprised primarily headcount reductions and the renegotiation of contracts with suppliers and vendors. The company is now working on a new $200-million cost-cutting plan with which it expects to realize around $50 million in 2019 and achieve $200 million annualized run-rate savings.
The Zacks Consensus Estimate for current-year earnings per share is pegged at $2.14 on revenues of $17.9 billion.
For 2020, the Zacks Consensus Estimate for earnings stands at $2.84 on $18.6 billion revenues, translating into respective 32.36% and 3.39% year-over-year growth.
The long-term earnings growth rate is expected at 23.2%, above the industry’s average of 14.9%, which is an upside for the company.
Shares of this Zacks Rank #2 (Buy) company have rallied 10.1% in a year's time, outperforming its industry’s rise of 5.9%.
UnitedHealth operates as a diversified health care company in the United States. In the last four reported quarters, the company delivered average beat of 3.39%.
Centene operates as a diversified and multi-national healthcare enterprise in the United States. It came up with average earnings surprise of 4.99% in the trailing four reported quarters.
WellCare Health offers managed care services to government-sponsored health care programs. The company pulled off average positive surprise of 15.43% in the preceding four reported quarters.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Here's Why You Should Add Tenet Healthcare to Your Portfolio
Tenet Healthcare Corp. (THC - Free Report) is well-poised for development on the back of strategic inorganic growth and cost-reduction plan.
Over the past 30 days, the company’s earnings estimates for 2019 and 2020 have been revised 17.6% and 13.6% upward, respectively. This in turn, reflects analysts' optimism on the stock.
The company flaunts a commendable earnings surprise history, having outpaced the Zacks Consensus Estimate in the trailing four reported quarters, the average being 1072.6%. This trend of consecutive estimate beats signifies the company’s operational efficiency.
The company is well-placed for growth, evident from its favorable VGM Score of A. Here V stands for Value, G for Growth and M for Momentum with the score being a weighted combination of all three factors.
Recently, the company delivered fourth-quarter 2018 adjusted net earnings of 51 cents per share, outperforming the Zacks Consensus Estimate by 112.5%. The top line has also beat the Zacks Consensus Estimate by 2.9%.
The company boasts a strong inorganic growth story. Tenet Healthcare has made numerous acquisitions, partnerships and strategic alliances, aimed primarily at boosting its scale of business, operating capacity and an expanding geographical presence. It has partnered with industry biggies like Cigna, Aetna, UnitedHealth, Humana et al.
In 2018, the company purchased the remaining ownership stake in United Surgical Partners International along with controlling interests in an ophthalmology surgery center in Pennsylvania, a single-specialty spine surgery center in Georgia, two multi-specialty surgery centers in Florida and one in Texas plus a specialty gastroenterology center in Florida. It also bought certain non-controlling ownership portions in a multi-specialty surgery center in California as well as in two surgical hospitals at Oklahoma.
Tenet Healthcare has also been divesting its businesses to focus on its core operations. The company is focused on selling its non-core and unprofitable business units to repay debt and maintain financial liquidity. Multiple divestitures made in the past three years have streamlined its operations and generated funds to clear debts.
The company sold nine Aspen facilities in the United Kingdom, eight hospitals in the United States last year and also completed the sale of three hospitals in the Chicago area earlier this January. The company has also been exploring its strategic alternatives for Conifer, which includes either a sale or a merger, a tax-efficient spin-off or a combination of alternative transactions.
The company also undertook cost-containment initiatives that helped it lower its targeted expenses in 2018. The cost-management program comprised primarily headcount reductions and the renegotiation of contracts with suppliers and vendors. The company is now working on a new $200-million cost-cutting plan with which it expects to realize around $50 million in 2019 and achieve $200 million annualized run-rate savings.
The Zacks Consensus Estimate for current-year earnings per share is pegged at $2.14 on revenues of $17.9 billion.
For 2020, the Zacks Consensus Estimate for earnings stands at $2.84 on $18.6 billion revenues, translating into respective 32.36% and 3.39% year-over-year growth.
The long-term earnings growth rate is expected at 23.2%, above the industry’s average of 14.9%, which is an upside for the company.
Shares of this Zacks Rank #2 (Buy) company have rallied 10.1% in a year's time, outperforming its industry’s rise of 5.9%.
Other Stocks to Consider
Investors interested in the medical sector can also take a look at some other top-ranked stocks like UnitedHealth Group Incorporated (UNH - Free Report) , Centene Corporation (CNC - Free Report) and WellCare Health Plans, Inc. , each currently carrying a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UnitedHealth operates as a diversified health care company in the United States. In the last four reported quarters, the company delivered average beat of 3.39%.
Centene operates as a diversified and multi-national healthcare enterprise in the United States. It came up with average earnings surprise of 4.99% in the trailing four reported quarters.
WellCare Health offers managed care services to government-sponsored health care programs. The company pulled off average positive surprise of 15.43% in the preceding four reported quarters.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>